Gazyva 2015 U.S Physician Engagement Report

Gazyva 2015 U.S Physician Engagement Report

  • July 2016 •
  • 23 pages •
  • Report ID: 4070787 •
  • Format: PDF

Pharmaceutical sales and marketing organizations face a challenging U.S. environment as physician access becomes increasingly restricted. Despite this major hurdle, personal promotion remains one of the most effective sales and marketing tools and it has never been more critical for drug and device makers to actively engage with physicians throughout the product lifecycle.

In order to address this critical issue, MDDetails leverages Sunshine Act disclosures (i.e., CMS Open Payments) to provide product and physician level promotional benchmarking across more than 500 marketed U.S. products. Each physician engagement report enables insight into personal promotional activity (e.g., education and detailing) for a specific product and its relevant peer set. Detailed analyses around coverage, specialty mix, rep access, and detailing frequency are provided. Furthermore, KOL engagement and ongoing market development activity (e.g., research, consulting, and speaking) is also discussed.

Report Scope

- A comprehensive assessment of Genentech physician engagement activity for Gazyva in 2015 (Over 7,800 paid interactions across 2,800 physicians)
- Promotional benchmarking (e.g. total reach and specialty mix) for Gazyva and 5 peer product(s) in key market(s), including: Chronic Lymphocytic Leukemia
- Longitudinal view of Gazyva interaction frequency and mix (e.g. meal, speaking, education, consulting, and research)
- In-depth analysis of Gazyva sales rep access within key specialties, including: Hematology/Oncology, Medical Oncology, and Internal Medicine
- Ranked lists of most engaged physicians, opinion leaders, and clinical researchers for Gazyva in 2015 (Up to the top 30 in each category)

Reasons to buy

- Understand the full breadth of market development and promotional activity for Gazyva and its competitors in 2015
- Gain insight into marketing mix, promotional spend and longitudinal trends
- Benchmark prescriber access and detailing frequency within key specialties and geographies
- Obtain top Gazyva sales targets and opinion leaders in 2015

We are very sorry, but an error occurred.
Please contact if the problem remains.